This is not the most recent version of the article. View current version (6 AUG 2013)

Intervention Protocol

You have free access to this content

Laquinimod for multiple sclerosis

  1. Dian He1,
  2. Kai Han2,
  3. Xiangdong Gao3,
  4. Shuai Dong3,
  5. Lan Chu1,*,
  6. ZhanHui Feng1,
  7. Shan Wu1

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010475


How to Cite

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Electrophysiology Center, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

*Lan Chu, Department of Neurology, Affiliated Hospital of Guiyang Medical College, No. 28, Gui Yi Street, Guiyang, Guizhou Province, 550004, China. chulan8999@sohu.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (06 AUG 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the effectiveness and safety profile of laquinimod as monotherapy or combination therapy versus placebo or approved disease-modifying drugs (DMDs) (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide) for modifying disease course in patients with multiple sclerosis (MS).